Baxter International Inc.

BAX · NYSE · USD

Can Baxter's broad-based return to growth and better cash generation outlast an unresolved infusion pump hold and a permanently smaller IV fluids market?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Broad participation across divisions

    The bull case is that demand improved everywhere at once rather than in one division, so the growth reflects the portfolio and not a single product or a soft comparison.

  • Balance sheet repair

    Rising cash generation and a smaller debt load give management room to reinvest in products and make small acquisitions once the leverage target is met.

  • Cost-driven margin recovery

    Cost cuts already taken and the sale of high-cost inventory give a scheduled path to better margins, so profit depends more on internal action than on market growth.

  • Pump correction progress

    The infusion pump fix has moved from an open investigation to tested corrections, and the older Spectrum pump keeps the customer relationship intact in the meantime.

Bear case

  • Pump hold lasting the year

    The bear case is that the pump fix takes so long that hospital customers switch suppliers, and the guidance assumes the lost revenue never returns this year.

  • Smaller IV fluids market

    Hospitals now use less IV fluid than before the hurricane, and management has stopped waiting for a rebound, shrinking a large and long-standing revenue base.

  • Pharma supply and mix

    Injectables cannot be shipped in full because of a contract manufacturer and a shift toward IV push, and the fastest-growing pharma business earns a thinner margin.

  • Earnings held up by one-offs

    The improved profit outlook relies on a tariff refund and on service fees from the sold kidney business, both of which fade, leaving the underlying base lower.

Bull and bear points

Growth & Execution

In short: Every segment grew last quarter, but the pump hold and pharma supply limits still constrain sales.

Bull · 2

  • Every segment and division grew in the second quarter

    Growth was spread across the portfolio instead of one division carrying the quarter, which makes the improvement less dependent on a single product line.

    Q2 FY2026 call

  • Full-year organic growth outlook raised to 2% to 3%

    Three months ago management guided to roughly flat organic sales for the year; it now expects growth, which suggests the second quarter was not a one-off.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Novum pump hold is unresolved and guidance assumes no restart

    With the large-volume pump off the market, customers keep evaluating competing systems, so the installed base that supports later set and service sales keeps eroding.

    Q3 FY2025 call

  • Injectables supply limited by a contract manufacturer into 2027

    The pharmaceuticals business is losing sales it cannot ship and cannot quickly replace, and management says the constraint lasts into next year, which delays any recovery.

    Q1 FY2026 call

Profitability & Financial Strength

In short: Cash generation and debt reduction are improving, while tariffs and sales mix keep gross margin depressed.

Bull · 2

  • Free cash flow more than doubled over the past year

    Free cash flow over the last 12 months was $678 million against $333 million a year earlier, which funds debt paydown and, eventually, small acquisitions.

    Filed financials

  • Cost actions and inventory roll-off support second-half margin

    Management expects margins to expand in the second half as cost cuts land and high-cost inventory sells through, so the improvement rests on actions already taken.

    Q1 FY2026 call
Bear · 2

  • Gross margin fell to 34.9% on tariffs and unfavorable mix

    Gross margin was 34.9% in the latest quarter, and tariffs cost about $80 million this year while the fastest-growing business, drug compounding, earns a lower margin.

    Q4 FY2025 call

  • Management declines to restate 2027 earnings growth

    The prior call said earnings would grow modestly in 2027; that is now deferred, and the raise to the 2026 outlook came from a tariff refund that does not repeat.

    Tone shiftQ1 FY2026 → Q2 FY2026

Market Position

In short: Baxter holds leading hospital positions and a firm order book, offset by a smaller IV fluid market.

Bull · 2

  • Pump corrections identified and entering verification testing

    Three months ago management could only report progress on the corrections; it now says the fixes are identified and being tested, the step before returning the pump to market.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Capital equipment order book remains strong with hospitals

    Healthcare Systems and Technologies revenue was $801 million, up 4.4%, and management reports a healthy order book with no change yet in U.S. hospital capital spending.

    Q2 FY2026 call
Bear · 2

  • IV fluid demand treated as permanently lower

    Management once expected hospital fluid use to recover toward prior levels; it now calls the lower level a new baseline and has resized the business around that demand.

    Tone shiftQ3 FY2025 → Q4 FY2025

  • Pricing contributes less as growth shifts to lower-margin products

    Baxter has leaned on price increases to support profit, and management now expects a smaller pricing contribution while drug compounding grows fastest.

    Q4 FY2025 call